Clinical Research Papers:

Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke

Han Dong, Zhi-Hao Wang, Na Zhang, Si-Da Liu, Jian-Jun Zhao and Song-Yan Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:109752-109761. https://doi.org/10.18632/oncotarget.18211

Metrics: PDF 1181 views  |   HTML 2738 views  |   ?  


Han Dong1,5, Zhi-Hao Wang1, Na Zhang2, Si-Da Liu3, Jian-Jun Zhao4,* and Song-Yan Liu5,*

1 Department of Geriatric Medicine, The First Affiliated Hospital of Jilin University, Changchun, China

2 Department of Electrical Diagnosis, The General Hospital of Fourth Hospital of Jilin University, Changchun, China

3 Department of Thoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

4 Department of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China

5 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China

* These authors have contributted equally to this study

Correspondence to:

Song-Yan Liu, email:

Keywords: ischemic stroke, Galectin-3, prognosis

Received: February 03, 2017 Accepted: May 01, 2017 Published: May 25, 2017


Aim: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients.

Methods: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores.

Results: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3.

Conclusion: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18211